curasan received FDA 510(k) clearance to market CERASORB Ortho FOAM synthetic bone material. The resorbable ceramic and porcine collagen-based product is cleared for the treatment of bone defects in the extremities and pelvis.
In 2Q16, the company announced its planned investment in expansion of sales and marketing activities in the U.S. and China. curasan’s U.S. subsidiary has completed a structural reorganization to support its dental and orthopaedics business within North America, where an enhanced U.S. presence is core to the company’s 2017 growth strategy.
curasan received FDA 510(k) clearance to market CERASORB Ortho FOAM synthetic bone material. The resorbable ceramic and porcine collagen-based product is cleared for the treatment of bone defects in the extremities and pelvis.
In 2Q16, the company announced its planned investment in expansion of sales and marketing activities in the U.S. and...
curasan received FDA 510(k) clearance to market CERASORB Ortho FOAM synthetic bone material. The resorbable ceramic and porcine collagen-based product is cleared for the treatment of bone defects in the extremities and pelvis.
In 2Q16, the company announced its planned investment in expansion of sales and marketing activities in the U.S. and China. curasan’s U.S. subsidiary has completed a structural reorganization to support its dental and orthopaedics business within North America, where an enhanced U.S. presence is core to the company’s 2017 growth strategy.
Copy to clipboard 
